Healios K.K. | Balance Sheet

Fiscal year is January-December. All values JPY Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
3,006
1,947
9,196
7,827
19,041
11,627
Total Accounts Receivable
17
22
21
19
-
149
Other Current Assets
3
96
108
228
248
549
Total Current Assets
3,026
2,064
9,325
8,074
19,288
12,326
Net Property, Plant & Equipment
19
121
124
154
161
173
Total Investments and Advances
7
84
238
247
241
2,384
Intangible Assets
992
899
801
700
6
15
Total Assets
4,044
3,168
10,488
9,175
19,696
14,980
ST Debt & Current Portion LT Debt
-
-
-
129
172
Income Tax Payable
101
-
21
23
75
Other Current Liabilities
88
476
1,059
620
1,053
Total Current Liabilities
189
476
1,081
772
1,301
Long-Term Debt
51
-
-
2,371
2,199
Provision for Risks & Charges
5
25
26
33
30
Deferred Taxes
2
7
4
4
3
Other Liabilities
735
-
-
-
-
Total Liabilities
982
507
1,110
3,181
3,533
Common Equity (Total)
3,062
2,661
9,377
5,994
16,164
Total Shareholders' Equity
3,062
2,661
9,377
5,994
16,164
Total Equity
3,062
2,661
9,377
5,994
16,164
Liabilities & Shareholders' Equity
4,044
3,168
10,488
9,175
19,696

About Healios

View Profile
Address
World Trade Center Building, 15/F
Tokyo Tokyo 105
Japan
Employees -
Website http://www.healios.co.jp
Updated 07/08/2019
Healios KK engages in the development and sale of ophthalmological surgery adjuvants. It aims to commercialize pharmaceutical hiPSC derived retinal pigment epithelium (RPE) cell transplantation for the treatment of age-related macular degeneration. The firm develops therapies for the regeneration of retinal function and to improve visual function in those affected with retinal degenerative diseases.